Solara Active Pharma Sciences Limited

NSE SOLARA.NS

Solara Active Pharma Sciences Limited EBIT Margin for the year ending March 31, 2024: -31.08%

Solara Active Pharma Sciences Limited EBIT Margin is -31.08% for the year ending March 31, 2024, a -1,172.90% change year over year. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.
  • Solara Active Pharma Sciences Limited EBIT Margin for the year ending March 31, 2023 was 2.90%, a 254.03% change year over year.
  • Solara Active Pharma Sciences Limited EBIT Margin for the year ending March 31, 2022 was -1.88%, a -109.69% change year over year.
  • Solara Active Pharma Sciences Limited EBIT Margin for the year ending March 31, 2021 was 19.41%, a 27.79% change year over year.
  • Solara Active Pharma Sciences Limited EBIT Margin for the year ending March 31, 2020 was 15.19%, a 33.87% change year over year.
Key data
Date EBIT Margin EPS (Basic) EPS (Diluted) Shares (Basic, Weighted)
Market news
Loading...
SV Wall Street
NSE: SOLARA.NS

Solara Active Pharma Sciences Limited

CEO Mr. Poorvank Purohit
IPO Date June 27, 2018
Location India
Headquarters Admin Block 27
Employees 2,156
Sector Healthcare
Industries
Description

Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India. The company offers APIs for anesthetics, anthelmintic, anti-arrhythmic agent, anti-asthmatic, anti-hypertensive, anti-inflammatory, anti-Parkinson, anti-viral, antibiotic, anticoagulant, anticonvulsant, antidepressant, antiemetic, antiepileptic, antifungal, antigout agent, antihistamine, antihyperlipoproteinemic, antimalarial, antimycotic, antineoplastic detoxifying agent, antiprotozoal agent, antipsoriatic, antipsychotic, antitubercular, antitussive, antiulcerative, anxiolytic, bile acid analogue, calcimimetic agent, cardiovascular agent, central nervous system agent, chronic alcoholism, chronic kidney disease, dopamine receptor antagonist, folate analog, hyperkalaemia, immunosuppressant, lipid regulating agent, loop diuretic, muscarinic agonist, neuromuscular, OAB treatment, phenylalanine reducer, recovery of stroke, tardive dyskinesia, treatment of glaucoma and hyperphosphatemia, tropical anti-infective, and type-II diabetes therapeutic categories. It also provides contract research and manufacturing services for APIs, including contract development and manufacturing, analytical services, impurity synthesis, and regulatory support. In addition, the company exports its products. It operates in the Asia Pacific, Europe, North America, South America, and internationally. The company was formerly known as SSL Pharma Sciences Limited and changed its name to Solara Active Pharma Sciences Limited in March 2017. Solara Active Pharma Sciences Limited was incorporated in 2017 and is based in Chennai, India.

Similar companies

AARTIDRUGS.NS

Aarti Drugs Limited

USD 4.67

-0.69%

SUVENPHAR.NS

Suven Pharmaceuticals Limited

USD 12.16

1.55%

SEQUENT.NS

Sequent Scientific Limited

USD 1.90

1.06%

JBCHEPHARM.NS

J. B. Chemicals & Pharmaceuticals Limited

USD 20.33

0.95%

SHILPAMED.NS

Shilpa Medicare Limited

USD 8.18

0.56%

StockViz Staff

February 2, 2025

Any question? Send us an email